Can Arvinas, Inc. and Pfizer Inc. scale protein degradation in oncology markets
FDA approves VEPPANU, the first PROTAC therapy. Discover how Arvinas, Inc. is reshaping breast cancer treatment strategies today.
Pharma & Biotech
Pharma & Biotech
Does Rhythm Pharmaceuticals, Inc. now lead the rare neuroendocrine obesity treatment space?
Discover how Rhythm Pharmaceuticals, Inc.’s EU approval of setmelanotide could redefine rare obesity treatment and what comes next for the market.
Pharma & Biotech
Is Noema Pharma AG building a multi-symptom menopause therapy platform with cendifensine?
Is Noema Pharma AG building a menopause therapy platform? Discover how cendifensine could reshape non-hormonal treatment strategies
Pharma & Biotech
Is BRC Therapeutics opening a new regulatory lane for cannabinoid-based CRPS therapies?
CRPS has no approved U.S. therapy. BRC-002 now has an FDA path, but proof of safety, efficacy, and dosing discipline still lies ahead.
Pharma & Biotech
Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?
MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.
Pharma & Biotech
Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy
Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.
Pharma & Biotech
What Chiesi’s $1.9bn KalVista deal reveals about the next phase of rare disease consolidation
Rare disease M&A is shifting from science risk to launch execution. Chiesi’s KalVista deal puts oral HAE therapy at the center.
Pharma & Biotech
Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.
Pharma & Biotech
What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy
Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.
Pharma & Biotech
How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.